The EACPT 2017 Congress was held in
Prague from 24th-27th June with 566 participants from all 5 continents - 28%
from beyond the European Region, from Australia to China, Japan and South Korea
to the USA. The Congress included 22 sessions with Keynote Lectures on current
issues for research, education and clinical practice on safe and effective use
of medicines.
Heart Failure (HF) is a leading cause
of death and disease in Europe. Its prevalence will continue to increase worldwide
with the ageing of populations and increasing adoption of “Western” lifestyles
in less developed countries. Congestive HF is the final consequence of a wide
range of disorders of the heart and circulation, including hypertension, atherosclerosis,
cardiomyopathy and heart valve disease.
 |
| Professor Jean-Sébastien Hulot |
Despite progress in treatments with conventional medicines and devices, there remains a need for new approaches to reverse severity and progression on ventricular dysfunction.
Through an active collaboration with
the Cardiovascular Research Center at Mount Sinai School of Medicine in New York
(Director Prof. Hajjar) the team of Professor
Jean-Sébastien Hulot in Paris is involved
in the development of new targeted molecular therapies for heart failure.
In the video below you can hear
Professor Hulot discuss highlights from his EACPT Prague keynote lecture on
gene therapy and other new bio-therapies for heart failure.
Future EACPT Congresses:
- 2019 Stockholm
- 2021 Athens
- 2023 Rotterdam
The EACPT was founded 25 years ago and
now includes as members all national organisations for clinical pharmacology in
Europe, as well as organisations from further afield internationally. The EACPT
aims to provide educational and scientific support for the more than 4000
individual professionals interested in clinical pharmacology and therapeutics
throughout the European region, with its congresses attended by a global
audience. The EACPT also advises policy makers on how the specialty can
contribute to human health and wealth.
Clinical Therapeutics, the Official
Journal of EACPT.
No comments:
Post a Comment